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CObjective: Although utility-based algorithms have been developed for
the Functional Assessment of Cancer Therapy (FACT), their properties are
not well known compared with those of generic utility measures such as
the EQ-5D. Our objective was to compare EQ-5D and FACT preference-
based scores in cancer patients. Methods: A retrospective analysis was
onducted on cross-sectional data collected from 472 cancer patients who
ompleted both FACT-General and the EQ-5D. Preference-based scores
ere calculated by using published scoring functions for the EQ-5D (Dolan
. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–
08; Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health
tates: development and testing of the D1 valuation model. Med Care
005;43:203–20) and FACT (Dobrez D, Cella D, Pickard AS, et al. Estimation
f patient preference-based utility weights from the Functional Assess-
ent of Cancer Therapy-General. Value Health 2007;10:266–72; Kind P,
acran S. Eliciting social preference weights for Functional Assessment of
ancer Therapy-Lung health states. Pharmacoeconomics 2005;23:1143–
3; Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese
ersions of the Functional Assessment of Cancer Therapy-General to the
Q-5D utility index. Value Health 2009;12:371–6). Scores were compared
n the basis of clinical severity by using Eastern Cooperative Oncology
roup performance status ratings by physicians and patients. Relative O
mes
al So
oi:10.1016/j.jval.2011.11.029fficiency of each scoring function was examined by using ratios of F
tatistics. Results: Mean scores for the overall cohort were lowest
hen using Kind and Macran’s FACT UK societal algorithm (0.55,
D 0.09) and highest when using Dobrez et al.’s FACT US patient algo-
ithm (0.83, SD 0.08). Mean difference scores associated with clinical
everity, when extrapolated to quality-adjusted life-years (QALYs), had
range of 0.18 QALYs gained using FACT (Kind and Macran) to 0.45
ALYs gained using the EQ-5D (Dolan). However, relative efficien-
ies suggested that FACT (Kind and Macran) scores may provide greater
tatistical power to detect significant differences based on clinical
everity. Conclusions: We found important differences in utilities
cores estimated by each algorithm, with FACT-based algorithms
ending to underestimate the QALY benefit compared with algo-
ithms based on the EQ-5D. These differences highlight some of the
hallenges in using disease-specific preference-based measures for
ecision making despite potentially more relevant disease-specific
ontent.
eywords: cancer, EQ-5D, health-related quality of life, health state
tilities, utility assessment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The ability to generate utility scores as an outcome in oncology
trials is essential to the conduct of cost-utility analyses. Utility
scores enable the calculation of quality-adjusted life-years
(QALYs) [1], a metric that adjusts time in a health state by the
desirability or preference for that health state to evaluate the
value and/or cost-effectiveness of treatments for cancer. The most
widely used utility measures are generic measures, particularly
the EQ-5D [2]. Numerous national value sets are available to score
the EQ-5D, with the most highly cited societal value sets being de-
rived from general population in the United Kingdom [3] and the
United States [4]. The EQ-5D has generally demonstrated validity
nd reliability in studies of cancer [5]. There are often instances,
however, when utility scores are desired but no preference-based
measure is used in a study, or the generic measure may lack re-
* Address correspondence to: A. Simon Pickard, Second City Outco
E-mail: simon.pickard@secondcityoutcomesresearch.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.sponsiveness to meaningful changes in health-related quality of
life. The former issue has fostered research focused on the map-
ping of non–preference-based disease-specific measures to ge-
neric measures that generate utility scores [6].
Preference-based scoring functions for cancer-specific mea-
sures include several for the Functional Assessment of Cancer
Therapy (FACT) [7], a well-established family of cancer-specific
measures. Originally developed by using methods based on psy-
chometric theory, the FACT scoring involves the summation of
ordinal-level responses to items belonging to each scale. This ap-
proach contrasts with the “utility” approach to health measure-
ment, where a summary score is derived by applying a utility func-
tion or set of preference weights assigned to the levels and
dimensions of the measure.
The preference-based algorithms published for the FACT sys-
tem have varied in their methods and rater perspective. Dobrez
Research, 414 N. Ridgeland Avenue, Oak Park, IL 60302, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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FACT-General based on time trade-off (TTO) scores directly elic-
ited for own health from US cancer patients. Kind and Macran [9]
derived a set of societal preference weights by directly eliciting
visual analogue scale (VAS) ratings from the general population in
the United Kingdom for a descriptive health classifier system
based on FACT-Lung (FACT-L). Cheung and colleagues mapped
both English and Chinese versions of FACT to the EQ-5D utility
scores and derived a single mapping function for both languages
based on three of the four summary scores from FACT.
Given the many differences between the EQ-5D and FACT-
based scoring functions, we would expect them to generate differ-
ent scores. The extent to which the scoring functions differ, how-
ever, has not been well documented or contrasted. Because
different decision makers have different needs, they may wish to
not only consider the value that each approach can contribute to
decision making but also understand how the metrics differ rela-
tive to each other, particularly with respect to statistical efficiency
and QALY calculations. Thus, our objective was to examine pref-
erence-based scores generated by EQ-5D and FACT scoring func-
tions to better understand the strengths and limitations of each
approach in valuing health.
Methods
Data
A retrospective analysis was conducted on a data set where pa-
tients completed both the EQ-5D and FACT. The cohort consisted of
534 cancer patients who participated in a US-based multicenter
symptom scale validation study, which has been previously de-
scribed [10]. Patients completed both instruments on the same day.
All patients had advanced cancer classified as relating to any 1 of 11
tumor sites: bladder, brain, breast, colorectal, head/neck, hepatobili-
ary/pancreas, kidney, lung, lymphoma, ovary, or prostate. Approxi-
mately equal proportions of male and female patients were recruited
for the non–gender-specific cancers.
Patients were recruited from six sites that were geographically
representative of National Comprehensive Cancer Network mem-
ber institutions, an alliance of National Cancer Institute–approved
comprehensive cancer centers: Duke University Medical Center,
Fred Hutchinson Cancer Research Center, Dana Farber Cancer In-
stitute, H. Lee Moffitt Cancer Center and Research Institute, and
Table 1 – Utility-based algorithms.
Author, year
[reference]
Measure Domains in measure
Dolan, 1997 [3] EQ-5D (3-level) Mobility, usual activities,
self-care, pain/discomfort
anxiety/depression
Shaw et al., 2005 [4] EQ-5D (3-level) Mobility, usual activities,
self-care, pain/discomfort
anxiety/depression
Dobrez et al., 2007 [8] FACT-G Physical well-being (PWB),
emotional well-being
(EWB), functional well-
being (FWB), social well-
being (SWB)
Kind and Macran,
2005 [9]
FACT – Lung
(FACT-L,
version 4)
PWB, EWB, FWB, SWB, Lung
component – symptoms
(LCS)
Cheung et al., 2009
[11]
FACT-G
(version 4)
PWB, EWB, FWB, SWB
FACT-G, Functional Assessment of Cancer Therapy-General.the Robert H. Lurie Comprehensive Cancer Center at Northwest-ern University. In addition, patients were recruited by members of
the Cancer Health Alliance of Metropolitan Chicago, a coalition of
four community support agencies serving the Chicago metropoli-
tan area. The Cancer Health Alliance of Metropolitan Chicago or-
ganizations provide social, emotional, and informational support
services to cancer patients free of charge and are unaffiliated with
a medical center or university. Each Cancer Health Alliance of Met-
ropolitan Chicago agency serves different geographical and so-
ciodemographic cancer patient populations.
Measures/algorithms
We compared the scores generated by five algorithms/scoring
functions, two of them based on the EQ-5D and three based on
responses to FACT (Table 1). They are described in greater detail
below.
EQ-5D
The EQ-5D descriptive system consists of five dimensions (Mobil-
ity, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/De-
pression), each with three levels (3L) of health [2]. The EQ-5D also
includes a 20-cm VAS, which asks the respondents to rate their
health today from 0 (worst imaginable health) to 100 (best imag-
inable health). A preference-based score is calculated from re-
sponses to the health state descriptive system that is typically
interpreted along a continuum where 1 represents best possible
health and 0 represents dead, with some health states being worse
than dead (0). Participants were asked to complete the standard
US English language EQ-5D (3L) and the VAS. The US and UK Eng-
lish language versions of the EQ-5D are nearly identical, differing
only in the instruction to place a tick (UK) or checkmark (US) in the
box that best describes your own health state today.
The EQ-5D preference-based scores were calculated by using
the algorithms developed by Dolan [3] from the general population
in the United Kingdom and by Shaw and colleagues [4] for the
United States. A ceiling effect is observed in milder health condi-
tions with the EQ-5D health classifier system [10,12], a limitation
that applies equally to both algorithms. The scores generated by
the Dolan UK value set range from 0.59 (for health state vector
33333, which represents the worst health state) to 1.0 (for health
state vector 11111, which represents full health), while the scores for
the US value set from Shaw and colleagues cover a smaller range of
Items/domains in
algorithm
Source of
utilities
Range of
possible values
bility, usual activities,
elf-care, pain/discomfort,
nxiety/depression
Societal (UK) 0.59 to 1.0
bility, usual activities,
elf-care, pain/discomfort,
nxiety/depression
Societal (US) 0.109 to 1.0
o items: PWB, Two items:
WB
Cancer patients
(US)
0.50–1.04
B, EWB, FWB, SWB, LCS Societal (UK) 0.18–0.70
le scores for PWB, EWB,
WB
Mapped from Dolan
1997 (UK societal)
0.238–0.982,
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Participants completed the FACT questionnaire by using a ver-
sion specific to their cancer diagnosis [7] The general subscales
common to all versions (FACT-G) include physical well-being,
social/family well-being, emotional well-being, and functional
well-being. Preference-based scores were generated by using the
FACT-G–based algorithm by Dobrez and colleagues [8], a prefer-
ence-based algorithm for the FACT-L by Kind and Macran [9], and
heung et al.’s [11] scoring function that predicted EQ-5D scores
from FACT-based summary scores. Although the latter is not a
preference-based algorithm, we included it for comparative pur-
poses.
The algorithm by Dobrez and colleagues is based on four items
from FACT-G that were selected on the basis of criteria that in-
cluded the extent of item correlation with TTO scores, Eastern
Cooperative Oncology Group (ECOG) performance status, the sig-
nificance of item coefficients, and testing using item-response
theory–based models. The modeling was conducted by using TTO
utilities directly obtained from 1433 cancer patients with 1 of 10
different diagnoses. The final additive model included two items
from physical well-being and two items from functional well-be-
ing subscales. The scale’s scores ranged from 0.50 to 1.04.
The VAS-based social preference weights for FACT-L by Kind
and Macran was based on a postal survey of 433 respondents from
the UK general population. A reconfigured descriptive system was
created for FACT-L by consulting with experts and using factor
analysis. The final model included 10 items, with at least one from
each of the four FACT-G scales and one item from the additional
concerns subscale “short of breath.” The summary index–based
scores ranged from a minimum of 0.111 to a maximum of 0.703. As
in this study, the algorithm may be modified to apply more broadly
to all cancer patients with the assumed response “not at all” to the
“short of breath” item if patients completed FACT-G rather than
FACT-L, resulting in a scale score ranging from 0.182 to 0.703.
The function for mapping FACT-G scores to EQ-5D index-based
scores by Cheung et al. [11] was based on a survey of 558 cancer
patients in Singapore. Regression models mapped the English and
Chinese versions of FACT-G scale scores for physical, emotional,
and functional well-being to the EQ-5D index-based score. It was
concluded that a single mapping function could be used for both
language versions.
ECOG
Performance status was evaluated by using the ECOG classifica-
tion system [13]. The ECOG scale is used by physicians and re-
earchers to determine progression of disease, impact of the dis-
ase on daily activities, and guide appropriate treatment and
rognosis. Performance status is based on a score that ranges from
(fully active) to 5 (dead). Although ECOG performance status is
ypically assessed by clinicians, in this study patients were also
sked to rate their ECOG status.
Analysis
The distribution of scores generated by each utility algorithm was
described by using summary statistics including min, max, mean,
median, SD, and range of scores. Ceiling and floor effects were
examined among subjects whose responses were entirely at the
top or the bottom of the descriptive system associated with each
algorithm. Correlations between EQ-5D and FACT preference-
based scores and ECOG performance status were assessed by us-
ing Spearman’s rho (rs) or Pearson’s correlation coefficient (r)
hen appropriate. Strength of correlation was interpreted as fol-
ows: absent (0.2), weak (0.2–0.34), moderate (0.35–0.5), and
trong (0.5) [14].
For insight into the discriminative ability of each algorithm, the
ohort was stratified by ECOG subgroups and mean scores re- corted in terms of absolute difference and magnitude of difference
effect size) between subgroups. Effect size was calculated on the
asis of difference in mean scores for adjacent ECOG subgroup
ivided by a pooled SD that weighted by sample size of each sub-
roup. For each preference-based scoring function, one-way
NOVA was used to test for statistically significant differences in
cores according to clinical severity using the ECOG status. To
ompare the relative statistical efficiency of the algorithms, rela-
ive efficiency (RE) ratios were calculated on the basis of ratios of F
tatistics [15]. A higher RE implies greater power to detect a statis-
ically significant difference between groups.
Results
Among respondents with complete data (n  472), the mean age
was 57 (SD 12) years and 54% were males (Table 2). The ECOG level
was rated by all patients (n 534) and by physicians for 91% of the
atients (n  472), that is, 9% were missing. Compared with phy-
ician ratings, a significantly greater proportion of patients rated
heir ECOG status as more severe (P  0.001; Wilcoxon signed
anks test).
The mean scores for the overall cohort generated by each algo-
ithm ranged from 0.553 (SD 0.086) for Kind and Macran’s FACT UK
ocietal algorithm to 0.827 (SD 0.084) for the FACT US patient al-
orithm (Table 3). If all scoring functions had the same range and
aximum scores, these results would imply that Kind and Mac-
an’s algorithm would provide the greatest opportunity for scores
o improve. The upper, lower, and range of the scale scores, how-
ver, differ between algorithms. The range of observed values was
argest for EQ-5D UK societal [1,14], more than double the range of
bserved scores for FACT UK societal by Cheung et al. (0.53), FACT
K societal by Kind and Macran (0.52), and Dobrez et al.’s FACT US
atient perspective (0.50). The compressed range of FACT-based
coring algorithms restrict the extent to which utility scores can
Table 2 – Respondent characteristics, all cancer patients
(n = 472).
Characteristic
Age (y), mean (SD) 57 (13)
Gender (female), n (%) 216 (46)
Type of cancer, n (%)
Bladder 28 (6)
Brain 40 (10)
Breast 41 (9)
Head/neck 46 (10)
Hepatobiliary 48 (10)
Kidney 48 (10)
Lung 44 (9)
Lymphoma 40 (9)
Ovarian 40 (9)
Prostate 44 (9)
Colorectal 47 (10)
ECOG level (physician-rated), n (%)
0 131 (28)
1 253 (54)
2 73 (16)
3 15 (3)
ECOG level (patient-rated), n (%)
0 108 (23)
1 227 (48)
2 118 (25)
3 19 (4)
ECOG, Eastern Cooperative Oncology Group.hange compared with the EQ-5D.
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the FACT descriptive system. When stratifying the 17% of patients
at the top of the EQ-5D descriptive system by ECOG subgroup, a
ceiling effect was observed. Among the 17% of patients who self-
reported full health on the EQ-5D, 57% were not rated as fully
active by physicians, that is, ECOG level 1, 2, or 3, and 44% of
patients rated themselves as not fully active. No floor effect was
detected on either measure.
In comparing mean scores across ECOG subgroups, the differ-
ence was the largest for EQ-5D UK societal scores (0.46), while the
smallest difference was observed for FACT US patient scores (0.13)
(Table 4). Kind and Macran’s algorithm and Cheng et al.’s scoring
function had the highest REs (RE  2.37 and 2.64, respectively,
sing the EQ-5D UK societal as the reference when stratified by
atient-rated ECOG subgroups) (Table 4). When the same analysis
as performed by using physician-rated rather than patient-rated
COG subgroups, similar results were observed in terms of the
elative performance of each scoring function (Table 5). The F sta-
istics indicated that greater discriminative ability was observed
hen subjects were stratified into ECOG subgroups that were pa-
ient rated rather than physician rated.
All the preference-based scores were moderately to strongly
orrelated, ranging from r  0.48 to r  0.99 (Table 6). Kind and
acran’s and Cheung et al.’s FACT-based scores were strongly
orrelated with EQ-5D scores (rs  0.67–0.69). Stronger correla-
Table 3 – Mean utility scores using EQ-5D and FACT-G algo
Score Mean
EQ-5D UK societal—Dolan 0.719
EQ-5D US societal—Shaw et al. 0.785
FACT US patient—Dobrez et al. 0.827
FACT UK societal—Kind and Macran 0.553
FACT UK societal mapped—Cheung et al. 0.749
IQR, interquartile range; min, minimum observed value; max, maxim
Table 4 – Utility scores by patient-rated ECOG status.
Algorithm ECOG
status
n Min Max
EQ-5D UK societal—Dolan 0 108 0.26 1
1 227 0.14 1
2 118 0.08 1
3 19 0.07 0.8
EQ-5D US societal— Shaw
et al.
0 108 0.51 1
1 227 0.21 1
2 118 0.33 1
3 19 0.26 0.83
FACT US patient—Dobrez
et al.
0 108 0.65 1.04
1 227 0.65 1
2 118 0.6 0.94
3 19 0.54 0.93
FACT UK societal—Kind
and Macran
0 108 0.46 0.70
1 227 0.31 0.69
2 118 0.29 0.65
3 19 0.28 0.56
FACT UK societal—Cheung
et al.
0 108 0.63 0.95
1 227 0.50 0.93
2 118 0.43 0.85
3 19 0.42 0.75
FACT, Functional Assessment of Cancer Therapy; RE, relative efficien
Eastern Cooperative Oncology Group.
* Difference in mean scores between ECOG levels 0 and 3.tions were observed between utility scores and patient ECOG
ratings (r 0.44 – 0.58) than between utility scores and physician
COG ratings (r  0.31– 0.42). Only moderate correlation was
bserved between physician- and patient-rated ECOG status
rs  0.43).
Discussion
This comparison of preference-based scores derived from the
EQ-5D and FACT descriptive systems found support for the con-
struct validity of each utility-based algorithm. Mean utility scores
increased monotonically with better clinical outcomes based on
the ECOG status, and moderate to strong intermeasure correla-
tions were observed. The utility scores generated by each algo-
rithm for the overall cohort and for ECOG performance status–
based patient subgroups generally differed to an extent that would
be considered meaningful [16]. The differences in mean scores
between ECOG subgroups for all algorithms tended to be larger
(effect sizes 0.80) with more functional impairment (Table 5),
which indicates a consistent pattern of substantial decline in pref-
erences for health states with more severe levels of functioning.
In comparing the mean scores of ECOG-based groups, the larg-
est difference in mean scores was obtained by using the EQ-5D UK
population-based algorithm by Dolan. If the results in Tables 4 and
s, all cancer patients (n = 472).
D Median (IQR) Min Max
227 0.727 (0.620–0.850) 0.14 1.00
154 0.804 (0.708–0.854) 0.21 1.00
084 0.852 (0.757–0.886) 0.54 1.04
086 0.564 (0.497–0.619) 0.28 0.70
113 0.760 (0.676–0.838) 0.42 0.95
bserved value.
ian Mean SD MD by ECOG
status
Effect
size
F statistic
(RE ratio)
5 0.87 0.15 0.46* 34.9 (1.0)
3 0.72 0.21 0.15 0.83
9 0.63 0.21 0.09 0.43
2 0.41 0.28 0.22 0.90
4 0.89 0.11 0.31* 39.2 (1.1)
0.78 0.14 0.11 0.88
7 0.72 0.14 0.06 0.43
0.58 0.18 0.14 0.88
9 0.89 0.08 0.13* 38.0 (1.1)
5 0.83 0.07 0.06 0.80
8 0.78 0.08 0.04 0.67
6 0.76 0.09 0.02 0.24
4 0.63 0.05 0.18* 82.6 (2.4)
7 0.56 0.07 0.07 1.17
9 0.49 0.07 0.07 1.00
7 0.45 0.08 0.04 0.53
6 0.85 0.07 0.25* 92.1 (2.6)
7 0.76 0.09 0.09 1.05
7 0.66 0.10 0.10 1.04
0 0.60 0.10 0.06 0.66
io using EQ-5D UK societal as reference; MD, mean difference; ECOG,rithm
S
0.
0.
0.
0.
0.Med
0.8
0.7
0.6
0.5
0.8
0.8
0.7
0.6
0.8
0.8
0.7
0.7
0.6
0.5
0.4
0.4
0.8
0.7
0.6
0.6
cy rat
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based on changes in ECOG status, then FACT-based algorithms
would tend to underestimate the QALY benefit compared with
algorithms based on the EQ-5D. For instance, using the mean
scores in Table 5, an improvement in ECOG status from 3 to 0
produces a benefit of 0.45 QALYs using the Dolan EQ-5D UK soci-
etal algorithm, compared with only 0.18 QALYs using Kind and
Macran’s FACT UK societal algorithm. Both Kind and Macran’s and
Cheung et al.’s FACT-based algorithms, however, demonstrated
greater relative statistical efficiency than did the other algorithms.
The greater REs are a function of the relatively smaller variance
associated with those algorithms. This suggests that these algo-
rithms may provide greater power to detect differences between
groups or over time in cohorts with small sample sizes.
Results supported the expectation that patient-based prefer-
ence scores would provide higher estimates of health-related
quality of life than would scores derived from societal preference
weighted algorithms. Past studies have found that the source of
preferences can influence values assigned to health states, that is,
Table 5 – Utility scores by physician-rated ECOG status.
Algorithm ECOG
status
n Min Max
EQ-5D UK societal—Dolan 0 131 0.02 1.00
1 253 0.07 1.00
2 73 0.14 1.00
3 15 0.09 0.69
EQ-5D US societal—Shaw et al. 0 131 0.31 1.00
1 253 0.26 1.00
2 73 0.21 1.00
3 15 0.40 0.78
FACT US patient—Dobrez et al. 0 131 0.65 1.00
1 253 0.60 1.04
2 73 0.65 1.00
3 15 0.54 0.89
FACT UK societal—Kind and
Macran
0 131 0.37 0.70
1 253 0.35 0.70
2 73 0.29 0.69
3 15 0.28 0.51
FACT UK societal—Cheung et
al.
0 131 0.51 0.95
1 253 0.44 0.94
2 73 0.42 0.92
3 15 0.47 0.69
FACT, Functional Assessment of Cancer Therapy; RE, relative efficie
Eastern Cooperative Oncology Group.
* Difference in mean scores between ECOG levels 0 and 3.
Table 6 – Correlation between preference-based scores.
EQ-5D
UK—Dolan
EQ-5D
US—Shaw et al.
EQ-5D US—Shaw et al. 0.99
FACT—Dobrez et al. 0.48 0.48
FACT—Kind and Macran 0.68 0.68
FACT—Cheung et al. 0.67 0.67
ECOG (physician) 0.34 0.34
ECOG (patient) 0.49 0.49
All P  0.01.
ECOG, Eastern Cooperative Oncology Group; FACT, Functional Assessmenpatient versus societal [17,18]. There are, however, many possible
explanations for the differences in utility scores generated by each
algorithm, including the attributes represented in the health state
classifier, the number of levels or categories per health state di-
mension, the method used to elicit utilities (e.g., VAS or time
trade-off), the study design/methodology, choice of utility func-
tion/modeling technique, and criteria to select the preferred sta-
tistical model. Although the conventional QALY model would
dictate that health states be valued on a scale where dead must be
0 and 1 represent perfect health [1], there are differences in the
calibration of measures. Studies have shown that generic utility
measures such as the EQ-5D, SF-36 and health utilities index gen-
erate different QALY estimates for the same group of patients
[12,19–21]. Previous studies that compared EQ-5D UK and US val-
ues sets reported differences in utility scores of the general popu-
lation [22,23]. Furthermore, the FACT US patient value set was
derived from TTO scores while the FACT UK societal value set was
derived from VAS scores, which are scaled differently [24]. Unlike
he EQ-5D, Kind and Macran’s and Dobrez’s FACT-based algo-
dian Mean SD MD by ECOG
status
Effect
size
F statistic
(RE ratio)
.85 0.80 0.19 0.45* 19.5 (1.1)
.73 0.72 0.22 0.08 0.39
.69 0.63 0.24 0.09 0.41
.52 0.45 0.20 0.18 0.83
.84 0.84 0.13 0.24* 22.4 (1.3)
.80 0.79 0.15 0.06 0.40
.77 0.72 0.16 0.07 0.45
.60 0.60 0.12 0.12 0.87
.85 0.86 0.08 0.14* 17.9 (1.0)
.85 0.82 0.08 0.04 0.47
.80 0.80 0.08 0.03 0.32
.71 0.73 0.08 0.07 0.81
.60 0.59 0.07 0.18* 37.3 (2.1)
.56 0.55 0.08 0.04 0.54
.52 0.51 0.09 0.05 0.54
.42 0.41 0.07 0.09 1.19
.82 0.80 0.10 0.23* 36.7 (2.1)
.76 0.75 0.10 0.05 0.54
.72 0.70 0.12 0.05 0.46
.56 0.57 0.07 0.12 1.35
atio (EQ-5D UK societal as reference); MD, mean difference; ECOG,
CT—Dobrez
et al.
FACT—Kind
and Macran
FACT
UK—Cheung
et al.
ECOG
(physician)
0.69
0.69 0.91
0.29 0.38 0.37
0.43 0.61 0.62 0.43Me
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
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(1), which could be considered criticisms of these models. On the
other hand, methodologies used to estimate EQ-5D value sets have
been criticized for the transformation of preferences for worse-
than-death health states before estimation [25].
There are strengths and limitations to each of the scoring func-
tions examined in this study. The scores based on EQ-5D UK soci-
etal and US societal value sets were similar, and the differences in
the observed scores may be attributed in part to the range of each
scoring function. An advantage of using the EQ-5D in cancer is that
the utility scores appear to span a broad range of values and suffer
no floor effects. Healthier cancer patients, however, are subject to
ceiling effects. Kind and Macran’s FACT UK societal value set dem-
onstrated the best ability to discriminate among patients stratified
by ECOG performance status, despite a limited range of scale
scores with a ceiling utility score of 0.70 for best health possible.
The discriminative ability appears to be related to the “corner-
stone” approach used to estimate utility weights for each item,
where disutility was estimated only for the worse level of each
dimension and then equal intervals were assigned to intermediate
levels of response, which resulted in an algorithm where it is pos-
sible to generate most of the numeric values along the scale con-
tinuum. Dobrez et al.’s FACT US patient algorithm consisted of
only four items and also suffered from a limited range of scale, but
it had an RE comparable to that of the EQ-5D scoring functions.
It is important to note that the use of an algorithm to generate
patient-derived utility scores generally serve a purpose different
from that served by societal preferences or QALY calculations, and
may be more likely or appropriate to be applied to clinical decision
making rather than for application in cost-utility analysis that in-
forms resource allocation across health care. This is not because
patient utilities lack validity per se, but because they may produce
an inadvertent bias against patients in resource allocation deci-
sions because of the “QALY trap” [26]. Specifically, because pa-
tient-derived utility scores tend to be higher than utility scores
obtained from societal weights, there is less potential to capture
the improvement associated with interventions that may help
cancer patients.
Several additional issues are relevant to this comparison of
algorithms. The study cohort consisted of patients with 11 differ-
ent types of cancer and at various stages of cancer, and this may
have limited generalizability to certain subgroups and cancers.
This study did not utilize the full potential range of scores derived
for the FACT-L UK societal algorithm [9], which included one dis-
ease-specific item that was not completed by most of the cohort,
and so we assumed “no problems” as a response to that item.
Thus, there is greater potential upside to the FACT-L algorithm
than that observed in this study if FACT-L responses rather than
FACT-G responses are available. Although the Cheung et al. algo-
rithm performed favorably compared with the EQ-5D, this is a
misleading finding. The mapping function is a biased estimator
of EQ-5D scores, predicting lower scores for the better health
states and higher scores for the poorer health states and smaller
SDs for all states. Thus, it has better discriminative power by
construction and should not be recommended in place of the
measure that it attempts to predict.
The physician-based ECOG ratings had lower correlations with
the preference-based scores than did patient-rated ECOG responses.
This result was not surprising as the same rater, the patient, provided
the ECOG rating and the health utility assessment. There is a sub-
stantial literature that acknowledges that health-care providers
and significant others can provide valid rating of health, and
agreement is acceptable on the more observable aspects of health
and functioning [27,28]. It is unclear whether the patient or clini-
cian rating is more desirable for the purpose of our study, because
both were useful as separate measures of severity of the patients.In conclusion, we found meaningful differences in index-basedutilities scores predicted by EQ-5D UK and US societal and FACT
UK societal and FACT US patient algorithms. Each algorithm has
its strengths and limitations, and the preferred choice of utility
algorithm will depend on the intended application. The present
study, however, illustrates one of the major impediments to the
uptake of disease-specific preference-based scoring functions.
Unlike the EQ-5D, a generic preference-based measure of health
that facilitates a standard currency for informing decisions in
health systems using cost-utility analysis, alternative preference-
based scoring functions create challenges for decision makers in
their interpretation despite potentially more relevant disease-spe-
cific content. There is still much opportunity for the development
of algorithms based on descriptive systems from disease-specific
measures such as FACT that improve upon the valuation ap-
proaches and sampling methods that have been used to this point.
Source of financial support: This study was financially sup-
ported by Abbott Laboratories.
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